Greenphire has announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution aims to streamline trial initiation for sponsors and CROs and eliminate guesswork during the budgeting process to deliver a smarter, more efficient workflow.
EnvisiX integrates with eClinicalGPS, Greenphire’s site payment solution, enabling simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.
“Greenphire is dedicated to engineering workflow and data solutions that transform business processes, reducing administrative burden and improving process effectiveness at each step of the clinical trial,” said Jim Murphy, Greenphire CEO. “With EnvisiX, stakeholders gain visibility and control over historically manual and fragmented budget build and negotiation workflows, ensuring improved speed and accuracy along the way.”
EnvisiX will enable sponsors and CROs to:
“For years, sponsors and CROs have expressed dissatisfaction with their study start-up processes. We have developed EnvisiX as a direct response to frustrations with the current workflows and solutions available in the market today,” said Kyle Cunningham, Chief Product Officer at Greenphire. “Our mission was to ensure that EnvisiX provides our customers with a streamlined and user-friendly experience for building a budget and ultimately to enable maximized confidence, defensibility and end-to-end efficiency via a direct integration and feedback loop with eClinicalGPS, the industry’s leading site payment solution.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.